비알코올성 지방간질환에서 nonalcoholic fatty liver diseases activity score (NAS)의 유용성 평가 및 임상적 요소와의 상관성
Validity and reliability of the nonalcoholic fatty liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors
1
조회
0
다운로드
2
인용
0
참고문헌
초록
Background/Aim: Nonalcoholic steatohepatitis (NASH) is commonly diagnosed using the semi-quantitative grading and staging system proposed by Brunt et al. in 1999. The Pathology Committee of the NASH established the nonalcoholic fatty liver diseases (NAFLD) activity score (NAS) in 2005. The aim of this study was to elucidate the validity and reliability of the NAS in Korean NAFLD patients. Methods: Fifty-six patients on whom sonography-guided liver biopsy for well-defined NAFLD was performed between 1999 and 2007 were identified retrospectively. Two pathologists evaluated each biopsy sample. NAFLD was evaluated using both the grading system developed by Brunt et al. and the NAS. Each pathologist was blinded to the patients’ clinical data and scored independently. We evaluated the body mass index (BMI), liver enzymes, lipid profile, peripheral insulin resistance, leptin, insulin/c-peptide ratio, ferritin, and fasting blood glucose. Results: The patients were aged 32.1±12.5 years (mean±SD) and comprised 44 males (78.6%). Patients with different grades at the two grading systems had mild steatosis or ballooning changes with fibrosis, and 36.6% of them were borderline cases (NAS of 3 or 4). The interobserver agreement on diagnostic category was 0.748 (P<0.001) for the NAS (using weighted κ statistics). Elevated fasting glucose, ALT, and triglyceride were associated with the NAS. Conclusions: The simple and reproducible NAS was found to be a useful pathologic grading system in Korean NAFLD patients. However, the proportion of borderline cases based on the NAS was high. The “wait and see” strategy is necessary for evaluating the long-term prognosis.
Abstract
Background/Aim: Nonalcoholic steatohepatitis (NASH) is commonly diagnosed using the semi-quantitative grading and staging system proposed by Brunt et al. in 1999. The Pathology Committee of the NASH established the nonalcoholic fatty liver diseases (NAFLD) activity score (NAS) in 2005. The aim of this study was to elucidate the validity and reliability of the NAS in Korean NAFLD patients. Methods: Fifty-six patients on whom sonography-guided liver biopsy for well-defined NAFLD was performed between 1999 and 2007 were identified retrospectively. Two pathologists evaluated each biopsy sample. NAFLD was evaluated using both the grading system developed by Brunt et al. and the NAS. Each pathologist was blinded to the patients’ clinical data and scored independently. We evaluated the body mass index (BMI), liver enzymes, lipid profile, peripheral insulin resistance, leptin, insulin/c-peptide ratio, ferritin, and fasting blood glucose. Results: The patients were aged 32.1±12.5 years (mean±SD) and comprised 44 males (78.6%). Patients with different grades at the two grading systems had mild steatosis or ballooning changes with fibrosis, and 36.6% of them were borderline cases (NAS of 3 or 4). The interobserver agreement on diagnostic category was 0.748 (P<0.001) for the NAS (using weighted κ statistics). Elevated fasting glucose, ALT, and triglyceride were associated with the NAS. Conclusions: The simple and reproducible NAS was found to be a useful pathologic grading system in Korean NAFLD patients. However, the proportion of borderline cases based on the NAS was high. The “wait and see” strategy is necessary for evaluating the long-term prognosis.
참고문헌 (27)
- Angulo P, "Nonalcoholic fatty liver disease", N Engl J Med, 346, pp.1221~1231 (2002)
- Marchesini G, "Nonalcoholic fatty liver disease: a feature of the metabolic syndrome", Diabetes, 50, pp.1844~1850 (2001)
- Sanyal AJ, "AGA technical review on nonalcoholic fatty liver disease", Gastroenterology, 123, pp.1705~1725 (2002)
- Younossi ZM, "Nonalcoholic fatty liver disease: an agenda for clinical research", Hepatology, 35, pp.746~752 (2002)
- Bugianesi E, "Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma", Gastroenterology, 123, pp.134~140 (2002)
- Hashizume H, "Primary liver cancers with nonalcoholic steatohepatitis", Eur J Gastroenterol Hepatol, 19, pp.827~834 (2007)
- Ludwig J, "Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease", Mayo Clin Proc, 55, pp.434~438 (1980)
- Brunt EM, "Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions", Am J Gastroenterol, 94, pp.2467~2474 (1999)
- Matteoni CA, "Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
- Promrat K, "A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis", Hepatology, 39, pp.188~196 (2004)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- Jun SY, "Nonalcoholic steatohepatitis", Korean J of Hepatology, 9, pp.147~150 (2003)
- Jeen YM, "Pathology of nonalcoholic steatohepatitis", Korean J of Hepatology, 15, pp.122~130 (2009)
- Ludwig J, "The nomenclature of chronic active hepatitis: An obituary", Gastroenterology, 105, pp.274~278 (1993)
- Desmet VJ, "Classification of chronic hepatitis: diagnosis, grading and staging", Hepatology, 19, pp.1513~1520 (1994)
- Ishak KG, "Chronic hepatitis: Morphology and nomenclature", Modern Pathol, 7, pp.690~713 (1994)
- Scheuer PJ, "Classification of chronic viral hepatitis: A need for reassessment", J Hepatol, 13, pp.372~374 (1991)
- Rogers DW, "Hepatitis C virus does not cause steatohepatitis", Dig Dis Sci, 37, pp.1644~1647 (1992)
- Palmer M, "Effect of weight reduction on hepatic abnormalities in overweight patients", Gastroenterology, 99, pp.1408~1413 (1990)
- Dixon JB, "Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss", Hepatology, 39, pp.1647~1654 (2004)
- Stumvoll M, "Metabolic effects of metformin in non-insulin-dependent diabetes mellitus", N Engl J Med, 333, pp.550~554 (1995)
- Kugelmas M, "Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E", Hepatology, 38, pp.413~419 (2003)
- Park SH, "Nonalcoholic steatohepatitis: pathogenesis and treatment", Korean J Hepatol, 14, pp.12~27 (2008)
- Lindor KD, "Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial", Hepatology, 39, pp.770~778 (2004)
- Neuschwander-Tetri BA, "Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone", Hepatology, 38, pp.1008~1017 (2003)
- 이소영, "정상 간기능 수치를 보이는 비알코올지방간 환자의 임상특징", 대한소화기학회지, 52(3), pp.161~170 (2008), 대한소화기학회
- Mendler MH, "Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease", Liver International, 25, pp.294~304 (2005)